Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man
Lopera F, Marino C, Chandrahas AS, O'Hare M, Villalba-Moreno ND, Aguillon D, Baena A, Sanchez JS, Vila-Castelar C, Ramirez Gomez L, Chmielewska N, Oliveira GM, et al.. Nature Medicine, 2023-05-15
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
We characterized the world's second case with ascertained extreme resilience to autosomal dominant Alzheimer's disease (ADAD). Side-by-side comparisons of this male case and the previously reported female case with ADAD homozygote for the APOE3 Christchurch (APOECh) variant allowed us to discern common features. The male remained cognitively intact until 67 years of age despite carrying a PSEN1-E280A mutation. Like the APOECh carrier, he had extremely elevated amyloid plaque burden and limited entorhinal Tau tangle burden. He did not carry the APOECh variant but was heterozygous for a rare variant in RELN (H3447R, termed COLBOS after the Colombia-Boston biomarker research study), a ligand that like apolipoprotein E binds to the VLDLr and APOEr2 receptors. RELN-COLBOS is a gain-of-function variant showing stronger ability to activate its canonical protein target Dab1 and reduce human Tau phosphorylation in a knockin mouse. A genetic variant in a case protected from ADAD suggests a role for RELN signaling in resilience to dementia.
What this study adds
Evidence grade: Preliminary
This case report describes a man with an inherited Alzheimer-causing mutation who remained cognitively intact until age 67 and carried a rare RELN variant called COLBOS. The finding suggests a role for RELN signaling in resilience to dementia, but it comes from a single case and mouse work, so it is very early.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lopera, F., Marino, C., Chandrahas, A. S., O'Hare, M., Villalba-Moreno, N. D., Aguillon, D., et al. (2023). Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man. Nature Medicine. https://doi.org/10.1038/s41591-023-02318-3
Vancouver
Lopera F, Marino C, Chandrahas AS, O'Hare M, Villalba-Moreno ND, Aguillon D, et al. Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man. Nature Medicine. 2023. doi:10.1038/s41591-023-02318-3. PMID: 37188781.
BibTeX
@article{lopera2023-37188781,
author = {Lopera, F. and Marino, C. and Chandrahas, A. S. and O'Hare, M. and Villalba-Moreno, N. D. and Aguillon, D. and Baena, A. and Sanchez, J. S. and Vila-Castelar, C. and Ramirez Gomez, L. and Chmielewska, N. and Oliveira, G. M. and others},
title = {{Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man}},
journal = {Nature Medicine},
year = {2023},
doi = {10.1038/s41591-023-02318-3},
pmid = {37188781},
url = {https://doi.org/10.1038/s41591-023-02318-3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The male remained cognitively intact until 67 years of age despite carrying a PSEN1-E280A mutation.
- Like the APOECh carrier, he had extremely elevated amyloid plaque burden and limited entorhinal Tau tangle burden.
- He did not carry the APOECh variant but was heterozygous for a rare variant in RELN (H3447R, termed COLBOS after the Colombia-Boston biomarker research study), a ligand that like apolipoprotein E binds to the VLDLr and APOEr2 receptors.
- RELN-COLBOS is a gain-of-function variant showing stronger ability to activate its canonical protein target Dab1 and reduce human Tau phosphorylation in a knockin mouse.
- A genetic variant in a case protected from ADAD suggests a role for RELN signaling in resilience to dementia.
Why it matters
This case report describes a man with an inherited Alzheimer-causing mutation who remained cognitively intact until age 67 and carried a rare RELN variant called COLBOS. The finding suggests a role for RELN signaling in resilience to dementia, but it comes from a single case and mouse work, so it is very early.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthPreliminary
Limitations
A female sibling carrier showed less optimal protection and had a history of severe head injury, depression and hypothyroidism that may have affected her phenotype; the authors cannot rule out that other factors, including additional variants, contributed to the resilience phenotype.
How this study scored 59/100
Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 58 of the 98 points we could judge it on, which is 59 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Nature Medicine) |
| Journal's citation record | 4 / 4 | Nature Medicine: journal h-index 763 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 2 / 5 | Rated “preliminary” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 195 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 39.0 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 5 / 6 | Cited 28.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 9 other studies in this library |
| Still being cited | 3 / 4 | Cited 161 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Yakeel T. Quiroz: h-index 48 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 13 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37188781) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 58 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 58 of the 98 points we could judge it on is 59 out of 100. |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
9 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Genetics from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.